Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Morel

Showing results (111-120 of 156) with videos related to

Pageof 16
Sort By:
Seminars in Hematology|May 12, 2023
Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteriaSteven P Treon, Alessandra Tedeschi, Jesus San-Miguel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's MacroglobulinemiaMeletios Athanasios Dimopoulos, Morie A Gertz, Efstathios Kastritis, et al.
American Journal of Hematology|July 18, 2013
Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemiaStéphanie Poulain, Christophe Roumier, Sylvie Galiègue-Zouitina, et al.
Plos Genetics|June 2, 2012
EMT inducers catalyze malignant transformation of mammary epithelial cells and drive tumorigenesis towards claudin-low tumors in transgenic miceAnne-Pierre Morel, George W Hinkal, Clémence Thomas, et al.
Leukemia & Lymphoma|April 12, 2017
A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasoneVéronique Leblond, Pierre Morel, Marie-Sarah Dilhuidy, et al.
Clinical Lymphoma & Myeloma|April 28, 2006
Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's MacroglobulinemiaEva Kimby, Steven P Treon, Athanasios Anagnostopoulos, et al.
Blood|February 29, 2020
A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosisMurielle Roussel, Giampaolo Merlini, Sylvie Chevret, et al.
European Journal of Cancer (Oxford, England : 1990)|December 5, 2025
Waldenström's macroglobulinemia: The LYSA pragmatic guidelinesDamien Roos-Weil, Cécile Tomowiak, Stéphanie Poulain, et al.
Seminars in Hematology|May 29, 2025
Report of Consensus Panel 3 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with high-risk diseasePrashant Kapoor, Meletios A Dimopoulos, Stephen M Ansell, et al.
Hematological Oncology|November 24, 2016
First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective studyGodelieve Meunier, Loic Ysebaert, Phi Linh Nguyen-Thi, et al.
Pageof 16

Showing results (111-120 of 156) with videos related to

Sort By:
Pageof 16
Seminars in Hematology|May 12, 2023
Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteriaSteven P Treon, Alessandra Tedeschi, Jesus San-Miguel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's MacroglobulinemiaMeletios Athanasios Dimopoulos, Morie A Gertz, Efstathios Kastritis, et al.
American Journal of Hematology|July 18, 2013
Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemiaStéphanie Poulain, Christophe Roumier, Sylvie Galiègue-Zouitina, et al.
Plos Genetics|June 2, 2012
EMT inducers catalyze malignant transformation of mammary epithelial cells and drive tumorigenesis towards claudin-low tumors in transgenic miceAnne-Pierre Morel, George W Hinkal, Clémence Thomas, et al.
Leukemia & Lymphoma|April 12, 2017
A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasoneVéronique Leblond, Pierre Morel, Marie-Sarah Dilhuidy, et al.
Clinical Lymphoma & Myeloma|April 28, 2006
Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's MacroglobulinemiaEva Kimby, Steven P Treon, Athanasios Anagnostopoulos, et al.
Blood|February 29, 2020
A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosisMurielle Roussel, Giampaolo Merlini, Sylvie Chevret, et al.
European Journal of Cancer (Oxford, England : 1990)|December 5, 2025
Waldenström's macroglobulinemia: The LYSA pragmatic guidelinesDamien Roos-Weil, Cécile Tomowiak, Stéphanie Poulain, et al.
Seminars in Hematology|May 29, 2025
Report of Consensus Panel 3 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with high-risk diseasePrashant Kapoor, Meletios A Dimopoulos, Stephen M Ansell, et al.
Hematological Oncology|November 24, 2016
First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective studyGodelieve Meunier, Loic Ysebaert, Phi Linh Nguyen-Thi, et al.
Pageof 16